# Appendix: Integrating public health surveillance and environmental data to model presence of Histoplasma in the United States

# 1 Additional Details

## 1.1 Histoplasmosis Case Definition (pre-2016)

The following table contains the histoplasmosis case definitions prior to 2016 for the states included in our analysis.

State	Pre-2016 definition			
	Clinical description	Confirmed	Probable	Suspect
Alabama	A case of acute pulmonary	Lab Criteria:	Lab Criteria:	Case
	histoplasmosis is defined as an	<ul> <li>Isolation of H. capsulatum from</li> </ul>	A single CF titer ≥1:32 and M	Classification:
	influenza-like illness with two	culture of sputum, urine, tissue,	band detection.	• An
	or more of the following	etc.		asymptomatic
	symptoms: fever/ chills, cough,	<ul> <li>Identification of organisms in</li> </ul>	Case Classification:	case that meets
	chest pain, and/or	tissues by histopathology.	<ul> <li>A case diagnosed as acute</li> </ul>	confirmatory
	myalgia/arthralgia.	• A fourfold rise between acute	pulmonary histoplasmosis	(confirmed) or
	Histoplasmosis infection may	and convalescent CF titers.	AND meets presumptive	presumptive
	also be asymptomatic or	Case Classification	(probable) lab criteria.	(probable) lab
	symptoms including abdominal	• A case diagnosed as acute	• A case with children in the symptoms (not	citteria.
	nain mediastinal	nulmonary histoplasmosis AND	diagnosed as acute nulmonary	
	lymphadenopathy	meets at least 1 of the	histoplasmosis) AND meets	
	hepatosplenomegaly, and skin	confirmatory lab criteria.	presumptive lab criteria.	
	lesions.	• A case with clinically compatible	• A case with clinically	
		symptoms (not diagnosed as	compatible symptoms, no	
		acute pulmonary histoplasmosis)	confirmatory lab evidence,	
		AND meets at least 1 of the	AND is epi-linked to suspected	
		confirmatory lab criteria.	source during an outbreak.	
		<ul> <li>Detection of H. capsulatum</li> </ul>		
		antigen in urine or serum. Results		
		of ≥2 EIA units or ≥0.6ng/mL are		
		considered positive.		
		• Detection of H and M band by		
		immunodiffusion.		N/ (A
Arkansas	N/A	Cases were considered to be	Cases were considered	N/A
		confirmed if the patient had a	probable if the patient has	
		and either courds, chest pain	histonlasmosis (self-reported	
		shortness of breath or abnormal	fever and either cough chest	
		CXR and at least one positive	pain, or shortness of breath)	
		culture, antigen, or serologic test	and at least one positive	
		for Histoplasma.	culture, antigen, or serologic	
			test for Histoplasma.	
			Because subclinical illness and	
			illness for which no	
			histoplasmosis tests were	
			performed were observed in	
			this outbreak, when a	
			confirmed case was identified,	
			case was breadened to	
			include any person exposed to	
			the site or event who also had	
			clinical features of fever	
			≥101°F (≥38.3°C) and at least	
			one of cough, chest pain,	
			shortness of breath, or	
			abnormal CXR within 3 weeks	
			of exposure, even in the	
			absence of laboratory testing	
		21/2	tor Histoplasma.	N/ (A
Delaware	N/A	N/A	N/A	N/A
Illinois	A case of acute respiratory	Acute Respiratory Histoplasmosis:	Acute Respiratory	N/A
	influenza like illness with two	A patient that is clinically	Histopiasmosis: A case that is	
	or more of the following	for H canculatum or bas a four	culture confirmed does not	
	symptoms: fever cough	fold rise in titers collected 2-4	have a four-fold rise in titer	
	shortness of breath or chest	weeks apart (numbers 1 or 2 in	but positive by any of the	
	pain.	laboratory criteria)	other laboratory methods	
			listed above (numbers 3-8 in	

Table 1: Histoplasmosis case definitions prior to  $2016\,$ 

State	Pre-2016 definition			
	Clinical description	Confirmed	Probable	Suspect
	Acute histoplasmosis may occur	Acute Disseminated	laboratory criteria). A case is	
	in the absence of respiratory	Histoplasmosis: A case that has	also considered probable with	
	symptoms. The symptoms of	fever and weight loss with or	clinically compatible	
	acute disseminated	without respiratory symptoms,	symptoms, no laboratory	
	histoplasmosis include fever	and a positive culture from an	confirmation, and an epi link	
	and weight loss.	extrapulmonary site.	to a suspected source during	
	_		an outbreak.	
			Acute Disseminated	
			Histoplasmosis: A case that	
			has fever and weight loss with	
			or without respiratory	
			symptoms, and evidence of H.	
			capsulatum by either	
			histopathology staining or	
			DNA probe of a specimen	
			from an extrapulmonary site.	
Indiana	Infections may take one of five	Lab Tests Sufficient for Case	N/A	N/A
	forms:	Confirmation:		
	<ul> <li>Asymptomatic - individual has</li> </ul>	<ul> <li>Culture - a positive culture for</li> </ul>		
	no clinical signs or symptoms,	Histoplasmosis capsulatum.		
	but as immunological evidence	<ul> <li>Histological - any pathological</li> </ul>		
	of infection.	finding indicating an infection		
	<ul> <li>Acute disseminated - is an</li> </ul>	with histoplasma.		
	illness of short duration that	<ul> <li>Complement-fixing antibodies -</li> </ul>		
	involves other organs in	presence of antibodies to yeast		
	addition to the lungs. It is	(Y) or mycelial (M) antigens in		
	marked by cough, exhaustion	dilutions greater than 1:16 in		
	and enlargement of the liver	patients with a compatible clinical		
	and spleen.	presentation and no other		
	<ul> <li>Acute benign respiratory -</li> </ul>	explanation for his/her illness.		
	characterized by weakness,	<ul> <li>Immunodiffusion testing - The</li> </ul>		
	fever, chest pains, and cough.	presence of H band antibodies is		
	Symptom severity is dependent	indicative of recent infection		
	on magnitude of exposure to	(within 6 months). The presence		
	fungal conidia.	of H band antibodies (with or		
	<ul> <li>Chronic disseminated - a</li> </ul>	without M band) with a		
	prolonged illness involving	compatible clinical presentation		
	organs other then the lungs. It	and no other explanation for		
	may include fever, anemia,	his/her illness.		
	hepatitis, pneumonia,	<ul> <li>Serum or urine antigen - A</li> </ul>		
	endocarditis, meningitis, and	positive test with a compatible		
	ulcers of the mouth, tongue,	clinical presentation.		
	nose, and larynx.			
	<ul> <li>Chronic pulmonary -</li> </ul>			
	resembles tuberculosis.			
Kentucky	A systemic fungal infection of	<ul> <li>Isolation of H. capsulatum from</li> </ul>	N/A	N/A
	varying severity caused by	culture of bone marrow, sputum,		
	Histoplasma capsulatum.	or lesions, OR		
	Infection may be asymptomatic	<ul> <li>Histological demonstration of</li> </ul>		
	or take one of four clinical	intracellular yeast cells from bone		
	forms:	marrow or tissue biopsy, OR		
	Acute benign respiratory -	Detection of H. capsulatum		
	mild respiratory illness with	polysaccharide antigen in urine or		
	general malaise, fever, chills,	serum, OR		
	headache, myalgia, chest pains,	<ul> <li>Rise in CF titers to either</li> </ul>		
	nonproductive cough and	histoplasmin or yeast-phase		
	scattered small calcifications of	antigen.		
	the lung.			
	<ul> <li>Acute disseminated -</li> </ul>			
	debilitating fever, GI symptoms,			
	bone marrow suppression,			
	lymphadenopathy. Most			
	frequent in children and			

Table 1: Histoplasmosis case definitions prior to 2016 (cont.)

State	Pre-2016 definition			
	Clinical description	Confirmed	Probable	Suspect
Michigan	Clinical description immunosuppressed; fatal if not treated. • Chronic pulmonary - clinically and radiologically resembles chronic pulmonary tuberculosis with cavitations, usually in middle-aged and elderly persons with underlying emphysema • Chronic disseminated - low- grade fever, weight loss, weakness, liver and spleen enlargement, mucosal ulcers, subacute course with slow progression; fatal if not treated. A case of acute histoplasmosis is defined as an influenza-like illness with two or more of the	Confirmed	Probable Lab Criteria: • Complement fixation titer to the yeast-phase antigen ≥1:32	Suspect N/A
	following symptoms: fever/chills, cough, chest pain, weakness, or myalgia/arthralgia.	<ul> <li>a clinically compatible illness</li> <li>coupled with laboratory evidence</li> <li>of infection.</li> <li>Lab Criteria:</li> <li>A four-fold rise in compliment</li> <li>fixation titer between serum</li> <li>specimens collected 2-4 weeks</li> <li>apart</li> <li>Identification of the organism in</li> <li>tissues by histopathology</li> <li>Isolation of the organism from</li> <li>cultures</li> </ul>	or • H band detected by Immunodiffusion testing or • Detection of antigen in body fluids including urine, serum, cerebral spinal fluid, and broncho-alveolar lavage fluid	
Minnesota	N/A	N/A	N/A	N/A
Mississippi	N/A	N/A	N/A	N/A
Nebraska	N/A	Lab Criteria: • Four-fold rise in complement fixation titer between acute and convalescent sera, OR • Culture isolation and confirmation of Histoplasma capsulatum from a clinical specimen, OR • Identification of Histoplasma capsulatum in tissue using an organism-specific PCR assay	Lab Criteria: • Complement fixation titer to the yeast-phase antigen ≥1:32, OR • H band detected by immunodiffusion testing, OR • Detection of antigen in a body fluid including urine, serum, csf, and bronchoalveolar lavage fluid, OR • Detection of characteristic yeast forms in tissue that are morphologically consistent with histoplasmosis, OR • Detection of characteristic intracellular yeast forms in a phagocyte in a peripheral blood smear	N/A
Pennsylvania	N/A	A case of histoplasmosis was defined as 1) a laboratory- confirmed H. capsulatum infection or 2) self- reported fever and two additional symptoms (i.e., headache, cough, chest pain, or difficulty breathing). Laboratory-confirmation was defined as either a urine or	N/A	N/A

Table 1: Histoplasmosis case definitions prior to 2016 (cont.)

State	Pre-2016 definition			
	Clinical description	Confirmed	Probable	Suspect
		serum Histoplasma antigen		
		enzyme immunoassay (EIA) test		
		result of >0.6 ng/mL.		
Wisconsin	A systemic fungal infection of	Clinically compatible illness with	N/A	N/A
	varying severity caused by	laboratory confirmation.		
	Histoplasma capsulatum.			
	Infection may be asymptomatic	Lab Criteria:		
	or take one of four clinical	Isolation of H. capsulatum from		
	forms:	culture of bone marrow, sputum,		
	Acute benign respiratory -	or lesions, OR		
	mild respiratory illness with	Histologic demonstration of		
	general malaise, fever, chills,	intracellular yeast cells from bone		
	headache, myalgia, chest pains,	marrow or tissue biopsy, OR		
	nonproductive cough and	Detection of H. capsulatum		
	scattered small calcifications of	polysaccharide antigen in urine or		
	the lung.	serum, OR		
	Acute disseminated -     debilitating four Claumatoms	Rise in CF titers to either		
	bono morrow suppression	antigon		
	bone marrow suppression,	A Desitive serelegy test for anti-H		
	frequent in children and	Positive servicely test for anti-H		
	immunosupprossed: fatal if not	band antibody		
	treated			
	Chronic nulmonary - clinically			
	and radiologically resembles			
	chronic nulmonary tuberculosis			
	with cavitations, usually in			
	middle-aged and elderly			
	persons with underlying			
	emphysema.			
	Chronic disseminated - low-			
	grade fever, weight loss,			
	weakness, liver and spleen			
	enlargement, mucosal ulcers.			
	subacute course with slow			
	progression; fatal if not treated.			

Table 1: Histoplasmosis case definitions prior to 2016 (cont.)

#### **1.2** Model Specification

The proposed model assumes for county i, the probability of the presence of H. capsulatum is given by

$$\psi_i = \Phi \left( \mathbf{X}_i \boldsymbol{\alpha} + \eta_i \right),$$

where  $\mathbf{X}_i$  is a vector of environmental covariates,  $\boldsymbol{\alpha}$  a vector of regression coefficients, and  $\eta_i$  a spatial random effect. It is well known that the spatial random effect can be confounded with the environmental variables [6]. To alleviate this confounding and reduce the dimension of the spatial random effect, we assume the spatial random effect depends on Moran's I basis functions [5, 3]. That is,

$$\psi_i = \Phi \left( \mathbf{X}'_i \boldsymbol{\alpha} + \mathbf{K}_i \boldsymbol{\gamma} \right), \tag{1}$$

where **K** is an  $n \times q$  matrix of Moran's I basis functions, and  $\gamma$  is a q-dimensional random effect.

Following Hughes and Haran (2013) [4], we assume  $\gamma$  is multivariate normal with mean zero and precision matrix  $\mathbf{K}'(\mathbf{D} - \mathbf{A})\mathbf{K}/\sigma^2$ , where  $\mathbf{A}$  is an adjacency matrix whose (i, j) element is 1 if county i and county j share a border and is 0 otherwise, and  $\mathbf{D}$  is a diagonal matrix whose (i, i)th entry is the total number of neighbors of county i. This form for the random effect  $\gamma$  along with the inclusion of the Moran's I basis functions yields conditional posterior distributions for  $\boldsymbol{\alpha}$  that have the same variance as under the non-spatial ordinary linear model and effectively removes confounding between the fixed and random effects, permitting interpretation of  $\boldsymbol{\alpha}$  as in the ordinary linear model.

Improper uniform priors on the real line were used for all regression coefficients, and inverse gamma prior distributions with parameters 0.5, 0.5 were assumed for the variance parameters  $\sigma^2$  and  $\tau^2$ . The temporal autocorrelation parameter  $\rho$  was assumed to follow a uniform distribution over (0, 1). The posterior distribution was simulated using a Markov chain Monte Carlo (MCMC) algorithm coded in Matlab. For computational efficiency, we employ the data augmentation approach of Albert and Chibb (1993) [1]. That is, we assume latent, Gaussian versions of the detection and occupancy processes, given by  $\tilde{Y}_{it}$  and  $\tilde{Z}_i$ , and then define  $Y_i = I\left(\tilde{Y}_{it} > 0\right)$  and  $Z_i = I\left(\tilde{Z}_i > 0\right)$ , where  $I(\cdot)$  denotes the indicator function. The data augmentation scheme permits Gibbs sampling updates in the MCMC algorithm. Convergence was assessed by visual inspection of trace plots.

Our model is also used to simulate from the posterior predictive distribution of  $\psi_i$  for counties in states outside of our study region. Doing so requires the availability of covariate information at these additional counties. In addition, the Moran's I basis functions must be computed as in [2] by initially included all locations of interest (those in the study area in addition to the counties to be predicted) and then subsetting the rows based on whether or not the corresponding county is in the study area. For county j not in the study area, draws are generated from the posterior predictive distribution of  $\psi_j$  by computing  $\psi_j = \Phi \left( \mathbf{X}'_j \boldsymbol{\alpha} + \mathbf{K}_j \boldsymbol{\gamma} \right)$ for each  $(\boldsymbol{\alpha}, \boldsymbol{\gamma})$  simulated by the MCMC algorithm.

## 2 Results

### 2.1 Reversible Jump MCMC

Reversible Jump MCMC was used to assist with variable selection and select the final subsets of covariates to be used for the occupancy and detection processes [7]. For the occupancy process, we initially considered the proportion of the county with land-cover of cultivated crops, the log of farm nitrogen, the log of non-farm nitrogen, the log of the mean elevation of the county, the latitude and longitude of the county centroid, the proportion of the county that is covered with water, and the proportion of the county that is undeveloped. For the detection process, we initially considered the proportion of the county with land-cover of cultivated crops, the average maximum temperature for the county in that month, soil moisture, the log of the population density, the log of the percent of the population that is non-white, the log of the percent of the population that is Latino, the proportion of the population with private insurance. We removed variables that had a relatively low estimated probability of inclusion following the RJMCMC algorithm. This led to the removal of undeveloped in the occupancy process and average maximum temperature, percent Latino, and percent working in construction from the detection process. The remaining variables were included in the final analysis.

#### 2.2 Additional Results

Below are plots of the estimated detection probabilities  $p_{it} = P(Y_{it} = 1 | Z_i = 1)$  for each county and each month in the study period. We see a lot of spatial heterogeneity in detection with strong temporal auto-correlation.



Figure 1: Estimated detection posterior probabilities for each county  $p_{it}$  for every month in 2011. The black outlined boxes are areas counties where at least one case of histoplasmosis was reported.



Figure 2: Estimated detection posterior probabilities for each county  $p_{it}$  for every month in 2012. The black outlined boxes are areas counties where at least one case of histoplasmosis was reported.



Figure 3: Estimated detection posterior probabilities for each county  $p_{it}$  for every month in 2013. The black outlined boxes are areas counties where at least one case of histoplasmosis was reported.



Figure 4: Estimated detection posterior probabilities for each county  $p_{it}$  for every month in 2014. The black outlined boxes are areas counties where at least one case of histoplasmosis was reported.

# References

- J.H. Albert and S. Chib. Bayesian analysis of binary and polychotomous response data. <u>Journal of the</u> American Statistical Association, 88(422):669–679, 1993.
- [2] Jonathan R. Bradley, Scott H. Holan, and Christopher K. Wikle. Multivariate spatio-temporal models for high-dimensional areal data with application to longitudinal employer-household dynamics. <u>The Annals</u> of Applied Statistics, 9(4):1761–1791, 2015.
- [3] S.A. Hepler and R. Erhardt. A spatiotemporal model for multivariate occupancy data. <u>Environmetrics</u>, 32(2), 2021.
- [4] John Hughes and Murali Haran. Dimension reduction and alleviation of confounding for spatial generalized linear mixed models. <u>Journal of the Royal Statistical Society: Series B (Statistical Methodology)</u>, 75(1):139–159, 2013.
- [5] Devin S Johnson, Paul B Conn, Mevin B Hooten, Justina C Ray, and Bruce A Pond. Spatial occupancy models for large data sets. Ecology, 94(4):801–808, 2013.
- [6] Brian J. Reich, James S. Hodges, and Vesna Zadnik. Effects of residual smoothing on the posterior of the fixed effects in disease-mapping models. Biometrics, 62(4):1197–1206, 2006.
- [7] Christian Robert and George Casella. <u>Monte Carlo statistical methods</u>. Springer Science & Business Media, 2013.